Multiple myeloma is an infection that, although not cured, has amplitudes and effective treatments.
Eduardo Najar
Agencia Latina de Noticias Medicina y Salud Pública
Thanks to the various advances in oncology medicine, there are some chronic pathologies that can be treated with the end to increase the quality of life of the patient, in the case of multiple myeloma, predominate in a group of therapies that need to be administered by the individual undergoing previa with the end to guarantee only a major prognostic without a systematic and systematic security.
In an interview with the journal Medicine and Public Health (MSP), Dr. Joel López, hematologist oncologist, details the advances in treatments for multiple myeloma, the diversity of therapies.
“Multiple myeloma is a condition that currently has no cure, the treatment is based on patient maintenance in a long-term remission, in the case of cases where therapy combinations are made at the end of which it is effective for a long time. tiempo ”, says the doctor.
Cambios in multiple myeloma therapy
To continue the exchange with determined therapy should be based on important and transcendental factors: a focus on the development of new diseases or complications in large numbers, which suelen be notaries of physical manner and other when the individual organism produces Sustainable determinants in the small scale that can be applied to their health.
Basically these patients do not have a cure, as it is important to realize a certain amount of pain while standing in a taper, (…). Cambian treatments for reasons, the first because the adverse effects are varied or on the contrary the patient has developed resistance to certain procedures and for this there is a progression to therapy. There are specific marketers of the protein that produces the flour that is needed and one that is extremely incremental in shape (mayor at 25%) changes therapy, ”the doctor said.
Además aggrego: “Clinically, too, an evaluation is being carried out if the patient has to present new comorbidities or indications of complications, there are biochemical indicators that are studied in the laboratory as the example of the protein and the mean”
Types of therapy
There is a significant number of treatments for multiple myeloma, which are used to guarantee the patient a favorable prognosis at large, the effectiveness of the measure depends on the individuality of the individual and the prevalent evaluations performed by the oncologist.
Since chemotherapy has been used less than direct therapy, the mayor uses several combinations (…), which can be reduced to radiotherapy with the end of what I can do with secondary effects in patients and one in other types of treatment of the intervention of orthopedic radiologists orthopedic surgeons to improve oseasous lesions (…), together with these immunological therapies (immunomodulators, inhibitors of protosomes, asteroids), with the finality of “, Said the specialist.
On the other hand, the specialist clarifies that there is a group of treatments that can be used at a prime moment, depending on the advance and prognosis that each patient presents and the stage of the condition.
“First-line therapies, such as an immunomodulatory combination, have been changed, we may add a monoclonal therapy, which together with the patient and the patient is not transplanted”, said the doctor
New treatments
The advances in respect to a nurse as the cancer has caused a great deal of progress in the last years, as the doctor mentions a recent therapy where used cells modified by the system with the end of treating malignant cells of the organism.
We believe that each day has the most therapies against multiple myeloma, using various methods of treatment, specifically monoclonal anticoagulants (…). Currently most are working on their therapies of immunological origin. We are ready to see the use of a new therapy where the patient’s cell lines are used, or the laboratory level is modified to attack myeloma cells, (…) we use the different immune system for this end, in EE. “UU is a reality and we hope that in Puerto Rico we will also have access soon”, concluded Dr. Joel López.